 This study is aimed at patients who received pazopanib in first-line metastatic cell renal cancer, so care clinical trial patients are excluded in the period from April 2011 date of approval of pazopanib in Spain to 30 June 2014, ie, before the presentation of CEICs in each hospital. In all cases, any decision to administer pazopanib therapy in first line will be taken according to local clinical practice and prior to the inclusion of patients in this retrospective study. 